FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Xvivo Perfusion AB (publ) Stock AnalysisComprehensive stock analysis for Xvivo Perfusion AB (publ) (XVIPF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisXVIPF
XVIPF
Xvivo Perfusion AB (publ)
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
XVIPF
Home🔹Stocks🔹Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ)

XVIPF•OTC

Xvivo Perfusion AB (publ)

XVIPF•OTC
Market cap
$607.94M
Sentiment

Your view on XVIPF

Mkt Cap
$607.94M
Sentiment
Your view
XVIPF
Xvivo Perfusion AB (publ)
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
XVIPF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Xvivo Perfusion AB (publ)

Industry
Medical - Devices
Sector
Healthcare
CEO
Christoffer Rosenblad
Headquarters
MAessans gata 10, Gothenburg, SE
Industry
Medical - Devices
Sector
Healthcare
CEO
Christoffer Rosenblad
Headquarters
MAessans gata 10, Gothenburg, SE
Description

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News